Main Menu

Parable Logo

Proton beam therapy in patients with breast cancer: evaluating early and late effects

Disease Site: Breast cancer.

Treatment Modality: Proton beam therapy, radiotherapy

Status: Open to Recruitment

Trial Details

PARABLE is a phase III, multi-centre, randomised trial which aims to compare proton beam therapy (PBT) with tailored radiotherapy to assess whether PBT can reduce mean heart dose (a validated biomarker of longer term serious heart toxicity) without increasing shorter-term side effects, in patients with breast cancer who have increased risk of radiotherapy-induced heart toxicity.  

192 patients will be recruited from UK sites over a 2.5 year period, with patients randomised to receive either PBT or tailored radiotherapy. PBT will be delivered either at The Christie NHS Foundation Trust or University College London NHS Foundation Trust. Patients will receive treatment for 3 weeks and will be followed up for a further 5 years.

Further Information

Chief Investigator: Professor Charlotte Coles, University of Cambridge

ICR-CTSU Scientific Lead: Professor Judith Bliss

Technical RT and Mechanistic Lead: Dr Anna Kirby, The Royal Marsden

Methodology Lead: Jo Haviland, ICR-CTSU

Trial Management Contact: [email protected] 


Sponsor: The Institute of Cancer Research

Funding: National Institute for Health Research (NIHR) – Efficacy and Mechanism Evaluation (EME) Programme (NIHR131120)

A lay summary in plain English is available from the National Institute for Health Research

NIHR Funding and Awards Search Website

Publications and Presentations

There have been no presentations or publications to date.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.